Company Profile
Innate Pharma Stock Price, News & Analysis
Company overview
Business overview
Innate Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Innate Pharma is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Innate Pharma follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Innate Pharma sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
IPHA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Innate Pharma now has a fairly clear sequence to watch across lacutamab, IPH4502, and the AstraZeneca-partnered programs. The biggest item is the planned Phase 3 start for lacutamab in cutaneous T-cell lymphoma, but the ADC data and the partnered Phase 3 readout also give the company more than one real marker to work through.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Source: Innate Pharma
- 02
Number of shares and voting rights of Innate Pharma as of April 16, 2026
Source: Innate Pharma
- 03
- 04
Innate Pharma reports full year 2025 financial results and business update
Source: Innate Pharma
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.